Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
FGB-C52H6 | Cynomolgus | Cynomolgus FGF R2 (IIIb) protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
FGB-H5256 | Human | Human FGF R2 (IIIb) protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
FGB-M52H5 | Mouse | Mouse FGF R2 (IIIb) protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
FGB-H5223 | Human | Human FGF R2 (IIIb) protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Biotinylated Human FGF-10, His,Avitag (Cat. No. FG0-H81Q7) immobilized on SA Chip can bind Human FGFR2 (IIIb), His Tag (Cat. No. FGB-H5223) with an affinity constant of 5.02 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Thyroid Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Medullary thyroid cancer (MTC); Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma | Details |
Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors | Details |
Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Central Nervous System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Endometrial Neoplasms; Lymphoma; Metastatic breast cancer; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Carcinoma; Stomach Neoplasms; Bone Marrow Neoplasms; Solid tumours | Details |
Selpercatinib | ARRY-192; Ret-IN-1; LOXO-292; LY-3527723 | Approved | Array Biopharma | Retevmo, Retsevmo | United States | Medullary thyroid cancer (MTC); Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms | Loxo Oncology Inc | 2020-05-08 | Medullary thyroid cancer (MTC); Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Hepatic Insufficiency; Neuroblastoma; Histiocytosis, Langerhans-Cell; Sarcoma, Ewing; Osteosarcoma; Fibrosarcoma; Sarcoma; Myofibromatosis; Wilms Tumor; Neoplasms; Thyroid Carcinoma, Anaplastic; Colonic Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Renal Insufficiency; Medulloblastoma; Ependymoma; Rhabdomyosarcoma; Hematologic Neoplasms; Solid tumours | Details |
Pemigatinib | INCB-054828; INCB-54828; IBI-375 | Approved | Incyte Corp | Pemazyre, 伯坦, 达伯坦 | United States | Cholangiocarcinoma | Incyte Corp | 2020-04-17 | Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Lymphoma, Non-Hodgkin; Glioma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Urologic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Colitis, Ulcerative; Translocation, Genetic; Breast Neoplasms; Biliary Tract Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Myeloproliferative Disorders; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Solid tumours; Bone Marrow Neoplasms | Details |
Tasurgratinib | E-7090 | Approved | Eisai Co Ltd | TASFYGO | Japan | Biliary Tract Neoplasms | Eisai Co Ltd | 2024-09-24 | Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency | Details |
Erdafitinib | 890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210 | Approved | Astex Pharmaceuticals Inc | Balversa, 博珂 | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Carcinoma, Squamous Cell; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Sarcoma; Glioma; Metastatic breast cancer; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Adenocarcinoma; Hepatoblastoma; Ependymoma; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Bone metastases; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Rhabdoid Tumor; Solid tumours; Glioblastoma; Carcinoma, Transitional Cell; Neoplasms; Wilms Tumor; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Prostatic Neoplasms, Castration-Resistant; Histiocytosis, Langerhans-Cell | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bemarituzumab | FPA-144 | Phase 3 Clinical | Five Prime Therapeutics Inc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
Rogaratinib | BAY-1163877 | Phase 3 Clinical | Bayer AG | Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
Infigratinib | BGJ-398; NVP-BGJ398 | Phase 3 Clinical | Novartis Pharma Ag | Pancreatic Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Gastrointestinal Stromal Tumors; Oropharyngeal Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Biliary Tract Neoplasms; Glioblastoma; Achondroplasia; Papillomavirus Infections; Neoplasms; Nasopharyngeal Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours | Details |
SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Zoligratinib | CH-5183284; FF-284; Debio-1347 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Breast Neoplasms | Details |
AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Thymus Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Fexagratinib | AZD4547; AZD-4547; ABSK-091; ABSK091 | Phase 2 Clinical | Astrazeneca Plc | Lymphoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Glioma; Uterine Neoplasms; Urinary Bladder Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms | Details |
Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
HH185 | 3D-185; 3-D185; HH-185; 3D185 | Phase 2 Clinical | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc | Solid tumours; Cholangiocarcinoma | Details |
3HP-2827 | 3HP-2827; 3HP2827 | Phase 2 Clinical | 3H (Suzhou) Pharmaceuticals Co Ltd | Solid tumours; Neoplasms | Details |
CGT-4859 | CGT4859; CGT-4859 | Phase 2 Clinical | Cogent Biosciences Inc | Solid tumours; Neoplasms; Cholangiocarcinoma | Details |
HMPL-453 | HMPL-453 | Phase 2 Clinical | Hutchison Medipharma Ltd | Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma | Details |
ABSK-061 | ABSK061 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Esophageal Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
Lirafugratinib | RLY-4008 | Phase 2 Clinical | Relay Therapeutics Inc | Solid tumours; Translocation, Genetic; Cholangiocarcinoma | Details |
PZH-2111 | PZH2111; PZH-2111 | Phase 2 Clinical | Zhangzhou Pientzehuang Pharmaceutical Co Ltd | Solid tumours; Cholangiocarcinoma | Details |
Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
BPI-17509 | BPI-17509 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
TYRA-200 | TYRA200; TYRA-200 | Phase 1 Clinical | Tyra Biosciences Inc | Solid tumours; Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms | Details |
Resigratinib | KIN-3248; KIN-003 | Phase 1 Clinical | Kinnate Biopharma Inc | Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Cholangiocarcinoma | Details |
BG-C137 | BG-C137 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours; Gastrointestinal Neoplasms | Details |
ACE-16229210 | ACE-16229210; ACE16229210 | Phase 1 Clinical | Acerand Therapeutics (Shanghai) Ltd | Solid tumours | Details |
MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis | Details |
TT-00434 | TT-00434 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours; Urinary Bladder Neoplasms | Details |
ABSK-121 | ABSK121-NX; ABSK121 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
LY-2874455 | LY-2874455 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms; Leukemia, Myeloid, Acute | Details |
CPL-304110 | CPL-304110; CPL-304-110 | Phase 1 Clinical | Celon Pharma Sa | Stomach Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Sarcoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.